Literature DB >> 15998673

Allogeneic mesenchymal stem cell transplantation in postinfarcted rat myocardium: short- and long-term effects.

Wangde Dai1, Sharon L Hale, Bradley J Martin, Jin-Qiang Kuang, Joan S Dow, Loren E Wold, Robert A Kloner.   

Abstract

BACKGROUND: Mesenchymal stem cells (MSCs) have the potential to replace infarct scar, but the long-term effects are unknown. We studied short- and long-term effects of MSC transplantation on left ventricular (LV) function in a rat myocardial infarction model. METHODS AND
RESULTS: Saline (n=46) or MSCs labeled with 1,1'-dioctadecyl-3,3,3'3'-testramethylindocarbocyanine perchlorate (DiI; n=49, 2x10(6) cells each) were injected into the scar of a 1-week-old myocardial infarction in Fischer rats. The presence and differentiation of engrafted cells and their effect on LV ejection fraction was assessed. At 4 weeks, LV stroke volume was significantly greater in the MSC-treated group (145+/-9 microL) than in the saline group (122+/-3 microL, P=0.032), and LV ejection fraction was significantly greater in MSC-treated animals (43.8+/-1.0%) than in the saline group (38.8+/-1.1%, P=0.0027). However, at 6 months, these benefits of MSC treatment were lost. DiI-positive cells were observed in the MSC group at 2 weeks and at 3 and 6 months. Expression of the muscle-specific markers alpha-actinin, myosin heavy chain, phospholamban, and tropomyosin was not observed at 2 weeks in DiI-positive cells. At 3 and 6 months, the DiI-positive cells were observed to express the above muscle-specific markers, but they did not fully evolve into an adult cardiac phenotype. Some of the DiI-positive cells expressed von Willebrand factor.
CONCLUSIONS: Allogeneic MSCs survive in infarcted myocardium as long as 6 months and express markers that suggest muscle and endothelium phenotypes. MSCs improved global LV function at 4 weeks; however, this benefit was transient, which suggests a possible early paracrine effect.

Entities:  

Mesh:

Year:  2005        PMID: 15998673     DOI: 10.1161/CIRCULATIONAHA.104.527937

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  161 in total

1.  Myocyte-depleted engineered cardiac tissues support therapeutic potential of mesenchymal stem cells.

Authors:  Gregory W Serrao; Irene C Turnbull; Damian Ancukiewicz; Do Eun Kim; Evan Kao; Timothy J Cashman; Lahouaria Hadri; Roger J Hajjar; Kevin D Costa
Journal:  Tissue Eng Part A       Date:  2012-06-25       Impact factor: 3.845

Review 2.  Stem cell therapy for ischemic heart disease.

Authors:  Mohammad Nurulqadr Jameel; Jianyi Zhang
Journal:  Antioxid Redox Signal       Date:  2010-10-28       Impact factor: 8.401

Review 3.  Stem cells and cardiac repair: a critical analysis.

Authors:  Jonathan H Dinsmore; Nabil Dib
Journal:  J Cardiovasc Transl Res       Date:  2008-01-31       Impact factor: 4.132

4.  Use of human embryonic stem cell derived-mesenchymal cells for cardiac repair.

Authors:  David L Simpson; Nolan L Boyd; Sunjay Kaushal; Steve L Stice; Samuel C Dudley
Journal:  Biotechnol Bioeng       Date:  2011-09-02       Impact factor: 4.530

5.  Intravenous administration of atorvastatin-pretreated mesenchymal stem cells improves cardiac performance after acute myocardial infarction: role of CXCR4.

Authors:  Na Li; Yue-Jin Yang; Hai-Yan Qian; Qing Li; Qian Zhang; Xiang-Dong Li; Qiu-Ting Dong; Hui Xu; Lei Song; Hao Zhang
Journal:  Am J Transl Res       Date:  2015-06-15       Impact factor: 4.060

6.  Long-term functional improvement and gene expression changes after bone marrow-derived multipotent progenitor cell transplantation in myocardial infarction.

Authors:  Mohammad Nurulqadr Jameel; Qinglu Li; Abdul Mansoor; Xiong Qiang; Aaron Sarver; Xiaohong Wang; Cory Swingen; Jianyi Zhang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-02-19       Impact factor: 4.733

Review 7.  Imaging stem cells implanted in infarcted myocardium.

Authors:  Rong Zhou; Paul D Acton; Victor A Ferrari
Journal:  J Am Coll Cardiol       Date:  2006-11-01       Impact factor: 24.094

8.  Mesenchymal stem cells and endothelial progenitor cells decrease renal injury in experimental swine renal artery stenosis through different mechanisms.

Authors:  Xiang-Yang Zhu; Victor Urbieta-Caceres; James D Krier; Stephen C Textor; Amir Lerman; Lilach O Lerman
Journal:  Stem Cells       Date:  2013-01       Impact factor: 6.277

9.  Comparison of transplantation of adipose tissue- and bone marrow-derived mesenchymal stem cells in the infarcted heart.

Authors:  Koen E A van der Bogt; Sonja Schrepfer; Jin Yu; Ahmad Y Sheikh; Grant Hoyt; Johannes A Govaert; Jeffrey B Velotta; Christopher H Contag; Robert C Robbins; Joseph C Wu
Journal:  Transplantation       Date:  2009-03-15       Impact factor: 4.939

10.  A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction.

Authors:  Joshua M Hare; Jay H Traverse; Timothy D Henry; Nabil Dib; Robert K Strumpf; Steven P Schulman; Gary Gerstenblith; Anthony N DeMaria; Ali E Denktas; Roger S Gammon; James B Hermiller; Mark A Reisman; Gary L Schaer; Warren Sherman
Journal:  J Am Coll Cardiol       Date:  2009-12-08       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.